Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry

Figure 1 Mortality rate in ASCERT registry by year in adjusted and unadjusted groups. A: Unadjusted analysis (relative risk with CABG); B: Adjusted analysis by inverse probability weighting (relative risk with CABG). Modified from Weintraub et al[15]. Comparative Effectiveness of Revascularization Strategies[15]. CABG: Coronary artery bypass surgery; PCI: Percutaneous coronary interventions.

Figure 2 ERACI III results by year. Death, acute myocardial infarction (AMI), major adverse cardiovascular events (MACCE) and target vessel revascularization (TVR) increase over time[20].

Figure 3 Increased rate of cardiac events at one, two, three and four years of follow-up in the syntax trial in both groups: drug eluting stent and coronary artery bypass surgery[21-23]. AMI: Acute myocardial infarction; CVA: Cerebrovascular accident; TVR: Target vessel revascularization; MACCE: Major adverse cardiovascular events; DES: Drug eluting stent; CABG: Coronary artery bypass surgery.

Figure 4 Reduction of cardiac events in all subgroups from COMPARE and SPIRIT IV trials with the use of everolimus-eluting stents[34,35]. ACS: Acute coronary syndrome; MI: Myocardial infarction; LAD: Left anterior descending artery; RVD: Reference vessel diameter; BMI: Body mass index.